Intesa Sanpaolo reviews outcomes from EBA’s 2025 EU-wide banking sector stress test

Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo Wikipedia
Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo - Wikipedia
0Comments

Intesa Sanpaolo announced its participation in the 2025 EU-wide stress test, an exercise coordinated by the European Banking Authority (EBA) in cooperation with the Single Supervisory Mechanism (SSM), the Bank of Italy, the European Central Bank (ECB), and the European Systemic Risk Board (ESRB).

The bank acknowledged the announcements made by the EBA regarding the stress test and confirmed it accepts the results of this process.

According to Intesa Sanpaolo, “The 2025 EU-wide stress test does not contain a pass-fail threshold and instead is designed to be used as an important source of information for the purposes of the SREP. The results will assist competent authorities in assessing Intesa Sanpaolo’s ability to meet applicable prudential requirements under stressed scenarios.”

The scenario used for this year’s adverse stress test was set by the ECB/ESRB and spans from 2025 through 2027. The methodology assumes a static balance sheet based on data as of December 2024. As noted by Intesa Sanpaolo, “It is not a forecast of Intesa Sanpaolo profits.”

The bank also provided information about its Common Equity Tier 1 ratio (CET1 ratio) as part of these results.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.